Telix Pharmaceuticals (TLX) Liabilities and Shareholders Equity (2023 - 2025)

Telix Pharmaceuticals (TLX) posted Liabilities and Shareholders Equity of $1.2 billion for Q4 2025, up 17.38% on a QoQ basis from $991.7 million in Q4 2024, and up 17.38% year-over-year from $991.7 million in Q4 2024.

Telix Pharmaceuticals (TLX) has 3 years of Liabilities and Shareholders Equity data on file, last reported at $1.2 billion in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 14.93 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 37.37 Mn
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 1.73 Bn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 78.88 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 33.89 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 26.48 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - 23.64 Mn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 40.87 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 5.13 Bn
10 Telix Pharmaceuticals 4.52 Bn 4.38 Bn - 1.16 Bn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 1.16 Bn
Dec 31, 2024 991.68 Mn
Dec 31, 2023 264.27 Mn